GlassScriptPhysician profile
Arunava Saha
NPI 1881265122
$2,279.80
in general payments reported to CMS, 2019-2025
17 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $857 · 2023: $657 · 2024: $234 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.28 | 2021-2025 | Rinvoq, Teflaro, Avycaz |
| Astrazeneca Pharmaceuticals LP | $449.40 | 2022-2023 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $333.21 | 2022-2025 | Opdivo, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.53 | 2021-2022 | |
| United Therapeutics Corporation | $157.02 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $137.23 | 2022 | |
| Gilead Sciences, INC. | $75.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.97 | 2022-2024 | Entyvio |
| Pfizer INC. | $71.85 | 2023-2024 | |
| Pulmonx Corporation | $61.38 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Alexion Pharmaceuticals, INC. | $50.39 | 2022-2023 | |
| Glaxosmithkline, LLC. | $42.86 | 2022-2023 | Trelegy Ellipta |
| Karyopharm Therapeutics INC. | $35.50 | 2022-2024 | Xpovio |
| Grifols USA, LLC | $34.58 | 2024 | Gamunex-C |
| Viiv Healthcare Company | $31.66 | 2023 | Dovato |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.83 | 2024 | Jynarque |
| Regeneron Healthcare Solutions, INC. | $14.49 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunava Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.